Skip to main content

Blog

Avidity Biosciences Submits Biologics License Application to FDA for del-zota

...

Inside the HHS Clinical Trials Roundtable: Why Speed, Access, and Rigor Matter for the Duchenne Community

...

Massachusetts Begins Newborn Screening for Duchenne

...

PPMD Joins FDA Leadership for Rare Disease Roundtable

...

Dyne Submits BLA to FDA for z-rostudirsen (DYNE-251) in Duchenne Amenable to Exon 51 Skipping

...

Dyne Announces Phase 3 Trial of Z-Rostudirsen, Plans for Submitting Biologics License Application to FDA

...

NEW: Livestream with the PAAC

...

GEMMABio Announces Duchenne Muscular Dystrophy Program, Shares Preclinical Data for Investigational Gene Therapy for Duchenne

...

REGENXBIO Shares Topline Results from Pivotal Phase III AFFINITY DUCHENNE® Study of RGX-202

...

Exercise in Dystrophinopathy: What Families Need to Know

...